Drug Trial Radar · NCT00377572
Inner-City Anti-IgE Therapy for Asthma
Last checked: Nov 19, 2026Latest source record: Mar 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
419
Actual
Start
Oct 2006
Primary completion
Dec 2009
Study completion Dec 2009
Sponsor
- Sponsor type
- NIH
- Collaborators
- Inner-City Asthma Consortium
- First posted
- Sep 18, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, care provider)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 years, up to 20 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to find out if adding omalizumab to standard asthma treatment results in a safer, more effective, and longer lasting asthma treatment strategy than standard treatment alone, in inner-city children with mild to severe asthma.
Conditions
- Asthma
Interventions
omalizumabBiological
Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
omalizumab placeboBiological
Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Number of Asthma Symptom DaysTime frame: Weeks 12-60: 12 months of assessments starting 12 weeks after the initiation of study treatment.
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
University of Arizona Health Sciences Center
Tucson, Arizona
National Jewish Medical and Research Center
Denver, Colorado
Children's National Medical Center
Washington D.C., District of Columbia
Children's Memorial Hospital
Chicago, Illinois
Boston University School of Medicine
Boston, Massachusetts
Columbia University Medical Center
New York, New York
Rainbow Babies and Children's Hospital
Cleveland, Ohio
University of Texas Southwestern Medical Center
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.